RATsIONAL'NYY VYBOR FARMAKOTERAPII POSTMENOPAUZAL'NOGO OSTEOPOROZA.EFFEKTIVNOST' I BEZOPASNOST' BONVIVY: OBZOR ZA VOSEM' LET PRIMENENIYa

• Main Authors: Zh E BELAYa, L Ya ROZhINSKAYa
• Format: Article
• Language: English
• Published: Endocrinology Research Centre 2013-12-01
• Series: Остеопороз и остеопатии
• Subjects: ибандронат; постменопаузальный остеопороз; бисфосфонат
• Online Access: https://endojournals.ru/index.php/osteo/article/view/8855

In this critical review, we have summarized the specific evidence on ibandronic acid (Bonviva) efficacy, tolerability, feasibility and safety acquired from randomized controlled clinical trials, meta-analyses, bridging trials, long-term extension studies, observational studies and clinical experience. We have paid special attention to reviewing the surrogate endpoints, which are routinely used in clinical practice to estimate the treatment efficacy as well as those high technology methods that are currently used in research centers to predict anti-fracture efficacy. Although the only registered indication for Bonviva in Russia is for postmenopausal osteoporosis, we have reviewed the available clinical trials on the efficacy of ibandronic acid to prevent postmenopausal osteoporosis, to treat low bone mass in males, to treat and prevent glucocorticoid induced osteoporosis and other types of secondary osteoporosis and, in particular, in patients after organ transplantation. In addition to this, we have extensively discussed the currently available data on the safety of pharmacologic treatment for osteoporosis.